Navigating through college isn’t easy for anyone, but it can be especially tricky for people with disabilities. Here are some quick tips to help those of you heading off to college this fall — as well as anyone considering attending university one day. 1. Pick a school you want to attend, not one you are . . .
Since its inception, MDA has invested more than $1 billion in neuromuscular disease research to uncover new treatments and cures. In 2016 alone, MDA awarded 66 new research, development and research infrastructure grants with a total funding commitment of more than $17 million. These and other MDA grants fund research projects designed to uncover the . . .
This summer MDA challenged our families, friends, sponsors, staff and others around the nation to share their stories about living life without limits despite the challenges of neuromuscular disease. Some shared moments tied to pursuing an education or career that was thought to be out of reach. Some talked about skydiving, hiking or running a . . .
Groundbreaking research plays a pivotal role in our mission to accelerate treatments and cures for muscular dystrophy, ALS and related life-threatening diseases. Each winter and summer, we award grants to researchers worldwide studying to make impacts across diseases. For our Summer 2016 Research Grants Cycle, we’re happy to announce $6.7 million in newly awarded funding. . . .
Marathon Pharmaceuticals has announced pivotal Phase 3 data evaluating the investigational drug deflazacort for the treatment of Duchenne muscular dystrophy in the journal Neurology. The study results show that deflazacort demonstrated significant improvement in muscle strength compared with placebo in 12 weeks. In addition, results show that deflazacort was associated with less weight gain than . . .
Osaka-based Mitsubishi Tanabe Pharma announced today that its New Drug Application (NDA) for the drug edaravone to treat people with ALS (amyotrophic lateral sclerosis) was accepted by the U.S. Food and Drug Administration. The Japanese pharmaceutical company said it expects a decision on whether it can market the drug in the United States by June 16, 2017. . . .
Happy shrieks erupted from the crowd as Payton Smotherman was wheeled into the mob of campers. “As soon as I pushed her into the group of people in her wheelchair, like four or five people all saw her and recognized her at once,” says Angela, Payton’s mom. She chuckled as she recalled diving out of . . .
Researchers are looking for boys and men living with Duchenne muscular dystrophy, ages 12 years and older, to participate in a phase 2 clinical trial, sponsored by FibroGen, to test the experimental drug FG-3019 (pamrevlumab). The study, known as “MissionDMD,” is designed to help researchers evaluate whether FG-3019 is safe and effective in people with . . .
I have been in education for thirty-six years, first as a student and now a teacher entering her seventeenth year in the classroom. Over the years, there have been hundreds of lessons that I’ve either learned or taught about living with spinal muscular atrophy and using a wheelchair. But there are four in particular that stick . . .
Starting a new school year is hard on every parent and child, but it’s particularly difficult when you have a child with special needs. As a parent you want to make sure that those needs are met all day every day, even if you are not with them. Even after you explain what your . . .
